ArticleMolecular and clinical oncology2022

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge.

Taku Nose et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.